Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|February 1, 2022

BioPharm International

  • BioPharm International, February 2022
  • Volume 35
  • Issue 2
  • Pages: 40

Ready-to-Use Disinfectant Wipes

STERIS Life Sciences’ VestaSyde SQ 64 st Ready-to-Use Disinfectant Wipes are part of a family of products designed to disinfect cleanroom services.

STERIS Life Sciences’ VestaSyde SQ 64 st Ready-to-Use Disinfectant Wipes are used to disinfect cleanroom surfaces. The wipes are part of a family of disinfectant products including concentrated and ready-to-use formats with the same quaternary ammonium active ingredient.

This product uses a system that combines cleanroom-quality wipes packaged with a separate internal pouch containing the quaternary ammonium active ingredient. The internal pouch allows for maximum chemical stability while still offering a method to saturate the wipes. By rolling the package of wipes, the internal pouch of liquid opens and quickly saturates the wipes. The wipes are low linting with a knitted polyester construction and ultrasonically sealed edges.

Each package of wipes is double-bagged and gamma irradiated to facilitate introduction into cleanroom areas. Every lot is USP sterility tested with complete lot traceability to meet quality assurance and quality control needs.

STERIS Life Sciences

www.sterislifesciences.com

Articles in this issue


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.